Gilead’s $5B Tubulis Deal Validates ADC Space – Bullish for Sutro Biopharma
Leerink sees major tailwind for Sutro Biopharma and initiates coverage with $38 price target.
/ 6 items
#ZYME↓
FDA Fast-Tracks Zymeworks’ New Ovarian Cancer Drug ZW191
Zymeworks receives U.S. FDA Fast Track Designation for ZW191, its FRα-targeting antibody-drug conjugate for advanced platinum-resistant ovarian cancer.
Ziihera GEA Trial: Modest Gains Come With Severe Side Effects
Jazz new stomach cancer drug extends survival by 7 months but causes severe side effects in 25% of patients. Ziihera-only combination failed to achieve statistical significance for overall survival at first analysis.
Wells Fargo Upgrades Relay Therapeutics and Zymeworks Stocks
Wells Fargo upgrades Relay Therapeutics and Zymeworks, raising price targets and highlighting potential 2026 growth from clinical data and cancer treatment opportunities.
Zymeworks & Jazz Pharmaceuticals Stocks Surge on Positive Cancer Trial Results
Zymeworks jumps 31% and Jazz Pharmaceuticals rises 26% after announcing successful Phase 3 trial results for Ziihera cancer treatment targeting stomach and esophageal cancers.
H.C. Wainwright Rates Zymeworks a Buy on Promising ZW191 Cancer Drug Data
H.C. Wainwright sets $26 price target for Zymeworks after Phase 1 data shows ZW191 cancer drug outperforms FDA-approved competitor with 44% response rate.